HHealthcare Read More Johnson & Johnson MedTech submits Ottava surgical robot to FDAJanuary 7, 2026 Johnson & Johnson MedTech (NYSE: JNJ) + announced today that it submitted its Ottava surgical robotic system to…
HHealthcare Read More The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & JohnsonJanuary 7, 2026 Chicago, IL – January 6, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog.…
HHealthcare Read More Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold ForeverDecember 31, 2025 Bristol Myers Squibb is a pharmaceutical giant with a solid dividend history. Medtronic is a high-yield medical device…
HHealthcare Read More Johnson & Johnson halts mid-stage trial of experimental eczema drugDecember 26, 2025 Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg |…
HHealthcare Read More Here’s Why Johnson & Johnson (JNJ) Surged in Q3December 25, 2025 Meridian Funds, managed by ArrowMark Partners, released its “Meridian Hedged Equity Fund” third-quarter 2025 investor letter. A copy of…
EEconomy Read More Stock market today: Live updatesDecember 17, 2025 Traders work on the floor of the New York Stock Exchange (NYSE) at the opening bell in New…
PPersonal finance Read More 5 Dividend Powerhouses That Belong in Every Retirement Portfolio Right NowDecember 11, 2025 24/7 Wall St Verizon offers the highest yield at 6.59% with a 0.32 beta and 19 consecutive years…
HHealthcare Read More Johnson & Johnson (JNJ) Announces Updated Results From the Phase 3 CARTITUDE-4 StudyDecember 10, 2025 Johnson & Johnson (NYSE:JNJ) is one of the best pharma stocks to invest in. Johnson & Johnson (NYSE:JNJ) announced…
HHealthcare Read More 1 Major Factor Behind the Healthcare Sector’s Recent SurgeDecember 10, 2025 Eli Lilly’s GLP-1 drug became the world’s best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other…
BBusiness Read More Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myelomaDecember 6, 2025 Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following…
HHealthcare Read More Johnson & Johnson Buys Prostate Cancer Treatment-Maker Halda for $3.1 BillionNovember 24, 2025 Johnson & Johnson has had the year 2025 circled, highlighted, bolded and underlined on its calendar for a…
BBusiness Read More What’s likely to move the market in the next trading sessionNovember 21, 2025 Stocks @ Night is a daily newsletter delivered after hours, giving you a first look at tomorrow and…